{"DataElement":{"publicId":"8013871","version":"1","preferredName":"Induction Therapy Received Type","preferredDefinition":"A response used to determine which first choice of treatment for a particular type of cancer was taken.","longName":"8013867v1.0:8013868v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"8013867","version":"1","preferredName":"Induction Therapy Receive","preferredDefinition":"The first choice of treatment for a particular type of cancer._To take, accept, or get something offered.","longName":"6942027v1.0:2241679v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"6942027","version":"1","preferredName":"Induction Therapy","preferredDefinition":"The first choice of treatment for a particular type of cancer.","longName":"C158876","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Induction Therapy","conceptCode":"C158876","definition":"The first choice of treatment for a particular type of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"92D8966C-A956-1CF7-E053-F662850A304A","latestVersionIndicator":"Yes","beginDate":"2019-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-18","modifiedBy":"ONEDATA","dateModified":"2019-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241679","version":"1","preferredName":"Received","preferredDefinition":"Received; taken, gotten, or acquired.","longName":"C25639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-2368-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-09","modifiedBy":"ONEDATA","dateModified":"2005-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67D25AC-28CD-1FBA-E053-4EBD850A6CA0","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"GARRIDOJ","dateModified":"2022-02-23","changeDescription":"Created for EA2183, 01/26/2022 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"8013868","version":"1","preferredName":"Induction Therapy Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"8013868v1.0","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CAPOX + Nivolumab","valueDescription":"CAPOX-Nivolumab Regimen","ValueMeaning":{"publicId":"8013869","version":"1","preferredName":"CAPOX-Nivolumab Regimen","longName":"8013869","preferredDefinition":"A chemoimmunotherapy regimen consisting of capecitabine and oxaliplatin (CAPOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CAPOX-Nivolumab Regimen","conceptCode":"C185315","definition":"A chemoimmunotherapy regimen consisting of capecitabine and oxaliplatin (CAPOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67D2B7A-B20F-2EB0-E053-4EBD850A72CB","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D67D2B7A-B22A-2EB0-E053-4EBD850A72CB","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","deletedIndicator":"No"},{"value":"FOLFOX + Nivolumab","valueDescription":"FOLFOX-Nivolumab Regimen","ValueMeaning":{"publicId":"8013870","version":"1","preferredName":"FOLFOX-Nivolumab Regimen","longName":"8013870","preferredDefinition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFOX-Nivolumab Regimen","conceptCode":"C185309","definition":"A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus nivolumab that can be used for the treatment of esophageal, esophagogastric junction and gastric cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67D2B7A-B236-2EB0-E053-4EBD850A72CB","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D67D2B7A-B251-2EB0-E053-4EBD850A72CB","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","deletedIndicator":"No"},{"value":"CAPOX","valueDescription":"CAPOX Regimen","ValueMeaning":{"publicId":"6847085","version":"1","preferredName":"CAPOX Regimen","longName":"6847085","preferredDefinition":"A regimen consisting of capecitabine and oxaliplatin used as a treatment for advanced stage colorectal cancer. This regimen differs from a similar regimen, XELOX, with regards to the dosing schedule for oxaliplatin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CAPOX Regimen","conceptCode":"C63596","definition":"A regimen consisting of capecitabine and oxaliplatin that can be used for the treatment of ampullary, appendiceal, pancreatic and small bowel adenocarcinomas, colorectal, gastric, esophageal and esophagogastric junction cancers, certain neuroendocrine tumors, occult primary tumors and mucinous carcinoma of the ovary. Low-dose CapeOX may be used for the treatment of gastric, esophageal and esophagogastric junction cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F717997-D3CC-1812-E053-F662850A6D71","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-06","modifiedBy":"ONEDATA","dateModified":"2019-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D67D2B7A-B267-2EB0-E053-4EBD850A72CB","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","deletedIndicator":"No"},{"value":"FOLFOX","valueDescription":"Fluorouracil/Leucovorin Calcium/Oxaliplatin","ValueMeaning":{"publicId":"3171720","version":"1","preferredName":"Fluorouracil/Leucovorin Calcium/Oxaliplatin","longName":"3171720","preferredDefinition":"One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FOLFOX Regimen","conceptCode":"C11197","definition":"One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DD02F2-6DAB-8DB6-E040-BB89AD430E72","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D67D2B7A-B273-2EB0-E053-4EBD850A72CB","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"ONEDATA","dateModified":"2022-01-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67D2B7A-B1F6-2EB0-E053-4EBD850A72CB","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"GARRIDOJ","dateModified":"2022-02-23","changeDescription":"Created for EA2183, 01/26/2022 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3852751","version":"1","longName":"Therapeutic","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000584","version":"1","longName":"Prior Treatment","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Induction therapy received","type":"Preferred Question Text","description":"Induction therapy received","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67D3894-9E61-2EAE-E053-4EBD850A7E13","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2022-01-26","modifiedBy":"GARRIDOJ","dateModified":"2022-02-23","changeDescription":"Created for EA2183, 01/26/2022 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}